10th Annual World Patient Safety, Science & Technology Summit Begins
2.6.2023 09:15:00 EEST | Business Wire | Press release
Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601006140/en/
Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire)
Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospitals. We’re all humans, we’re all a little bit competitive, and I think you react to data. This will make a difference.”
In a keynote address, Don Berwick, MD, MPP, FRCP, former administrator of the Centers for Medicare and Medicaid Services, pointed out that one in four hospital patients experience injury as a result of their care.
“Healthcare is far too unsafe,” said Berwick. “A large proportion of patient safety problems can be eliminated. There are hospitals in this nation that have driven certain kinds of infections to zero and virtually eliminated the risk of pneumonia from ventilation machines.”
Berwick suggested that healthcare systems can learn from many of the safety practices that the aviation industry has successfully put in place. “Today, you would have to fly continuously on a commercial flight for over 6,000 years to have a 50:50 chance of being injured as a passenger,” he said. “Roughly speaking, that means you are more than two million times safer in an airplane seat than in a hospital.”
Jannicke Mellin-Olsen, former president of the World Federation of Societies of Anesthesiologists, used her keynote address to call for more healthcare systems to involve patients and family members of those who have suffered harm in order to help drive better practices. “Involvement means hearing the patient voice at every level of the service,” she said.
The first day of the Summit also featured a talk from Sir Liam Donaldson, former chief medical officer of the United Kingdom, who discussed the impact of Covid-19 on patient safety and how the pandemic illustrated the lack of resilience throughout our healthcare structures. “There wasn’t much thinking about patient safety in the pandemic planning that preceded Covid,” said Donaldson. “Failures to develop world-class infection control facilities put both health workers and patients at risk, but there was also the issue of transitions of care, which greatly affected elderly patients and led to the virus spreading through nursing homes. That should have been part of our thinking from a patient safety perspective.”
Neelam Dhingra, who heads the World Health Organization’s (WHO) Transformative Flagship Initiative, emphasized the need to improve patient safety in low- and middle-income countries. Dhingra pointed out how when WHO conducted a survey of 102 countries in 2022, just 27% had developed a national patient safety action plan, and only 18% had established national targets on reducing medication-related harm.
“In low- and middle-income countries, we are still very far from even simple procedures when it comes to patient safety,” said Dhingra. “Studies from these countries are limited, but the estimates we have suggest that every minute at least five patients die in hospital. This means that the burden of harm in healthcare is grossly underestimated.”
Konrad Reinhart, founding president of the Global Sepsis Alliance, highlighted the continuing need to improve public awareness on sepsis and push for hospitals to comply with best practices. “Given the number of sepsis deaths worldwide, which are higher than cancer, the potential to reduce harm is enormous,” he said.
There were additional talks from world-renowned patient safety champion Peter Pronovost, along with Stephanie Mercado, chief executive officer of the National Association for Healthcare Quality, and Peter Lachman who leads the PSMF’s Fellowship Program. Tedros Adhanom Ghebreyesus, director general of WHO, addressed the Summit in a prerecorded video message.
Panel discussions included contributions from members of the President’s Council of Advisors on Science and Technology regarding their upcoming report on patient safety, as well as an assessment from healthcare leaders on the potential of predictive analytics and AI to improve patient safety.
Other panels touched on subjects ranging from the need for patient and family engagement in healthcare to proposals for forming a National Patient Safety Board. The day’s program ended with a private screening of the HBO documentary Bleed Out.
ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230601006140/en/
Contact information
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
